Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2015 | Nov. 09, 2015 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2015 | |
Document Fiscal Year Focus | 2,015 | |
Document Fiscal Period Focus | Q3 | |
Entity Registrant Name | Harvard Apparatus Regenerative Technology, Inc. | |
Entity Central Index Key | 1,563,665 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Trading Symbol | HART | |
Entity Common Stock, Shares Outstanding | 13,452,395 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 |
Current assets: | ||
Cash | $ 8,198 | $ 5,272 |
Related party receivables | 0 | 27 |
Accounts receivable | 59 | 5 |
Inventory | 144 | 207 |
Prepaid expenses | 82 | 317 |
Total current assets | 8,483 | 5,828 |
Property, plant and equipment, net of accumulated depreciation of $959 and $611, respectively | 1,202 | 1,376 |
Total non-current assets | 1,202 | 1,376 |
Total assets | 9,685 | 7,204 |
Current liabilities: | ||
Accounts payable | 220 | 370 |
Related party payables | 0 | 16 |
Accrued and other current liabilities | 111 | 324 |
Total current liabilities | 331 | 710 |
Total non-current liabilities | 0 | 0 |
Total liabilities | $ 331 | $ 710 |
Commitments and contingencies (note 7) | ||
Stockholders' equity: | ||
Convertible preferred stock, par value $0.01 per share, 2,000,000 shares authorized; 695,857 and 0 shares issued and 159,864 and 0 shares outstanding, respectively | $ 1,230 | $ 0 |
Common stock, par value $0.01 per share, 30,000,000 shares authorized; 12,652,075 and 7,856,607 shares issued and outstanding, respectively | 127 | 79 |
Additional paid-in capital | 30,453 | 19,449 |
Accumulated deficit | (22,449) | (13,035) |
Accumulated other comprehensive (loss) income | (7) | 1 |
Total stockholders' equity | 9,354 | 6,494 |
Total liabilities and stockholders' equity | $ 9,685 | $ 7,204 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 30,000,000 | 30,000,000 |
Common stock, shares issued | 12,652,075 | 7,856,607 |
Common stock, shares outstanding | 12,652,075 | 7,856,607 |
Property, plant and equipment, net of accumulated depreciation | $ 959 | $ 611 |
Convertible Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 2,000,000 | 2,000,000 |
Preferred stock, shares issued | 695,857 | 0 |
Preferred stock, shares outstanding | 159,864 | 0 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Revenues | $ 37 | $ 2 | $ 110 | $ 48 |
Cost of revenues | 18 | 1 | 55 | 25 |
Gross profit | 19 | 1 | 55 | 23 |
Operating expenses: | ||||
Research and development | 1,269 | 1,401 | 3,504 | 3,832 |
Sales and marketing | 86 | 77 | 276 | 241 |
General and administrative | 956 | 1,199 | 5,686 | 4,165 |
Total operating expenses | 2,311 | 2,677 | 9,466 | 8,238 |
Operating loss | (2,292) | (2,676) | (9,411) | (8,215) |
Other expense, net | 0 | (4) | (3) | (4) |
Loss before income taxes | (2,292) | (2,680) | (9,414) | (8,219) |
Income taxes | 0 | 0 | 0 | 0 |
Net loss | $ (2,292) | $ (2,680) | $ (9,414) | $ (8,219) |
Basic and diluted net loss per share (in dollars per share) | $ (0.19) | $ (0.34) | $ (0.91) | $ (1.05) |
Weighted average common shares, basic and diluted (in shares) | 11,974 | 7,851 | 10,395 | 7,809 |
Comprehensive loss: | ||||
Net loss | $ (2,292) | $ (2,680) | $ (9,414) | $ (8,219) |
Foreign currency translation adjustments | 0 | (3) | (8) | 0 |
Total comprehensive loss | $ (2,292) | $ (2,683) | $ (9,422) | $ (8,219) |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2015 | Sep. 30, 2014 | |
Cash flows used in operating activities: | ||
Net loss: | $ (9,414) | $ (8,219) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation expense | 3,612 | 1,926 |
Depreciation | 347 | 256 |
Changes in operating assets and liabilities: | ||
Decrease in related party receivables | 27 | 19 |
Increase in accounts receivable | (54) | (29) |
Decrease (increase) in inventories | 63 | (119) |
Decrease in prepaid expenses and other current assets | 235 | 274 |
(Decrease) increase in accounts payable | (150) | 10 |
Decrease in related party payables | (16) | (58) |
(Decrease) increase in accrued and other current liabilities | (212) | 269 |
Net cash used in operating activities | (5,562) | (5,671) |
Cash flows used in investing activities: | ||
Additions to property, plant and equipment | (175) | (1,033) |
Net cash used in investing activities | (175) | (1,033) |
Cash flows from financing activities: | ||
Proceeds from issuance of convertible preferred stock, net | 5,357 | 0 |
Proceeds from issuance of common stock, net | 3,314 | 418 |
Net cash provided by financing activities | 8,671 | 418 |
Effect of exchange rate changes on cash | (8) | 0 |
Net increase (decrease) in cash | 2,926 | (6,286) |
Cash at the beginning of the period | 5,272 | 14,008 |
Cash at the end of the period | $ 8,198 | $ 7,722 |
Overview and Basis of Presentat
Overview and Basis of Presentation | 9 Months Ended |
Sep. 30, 2015 | |
Accounting Policies [Abstract] | |
Business Description and Basis of Presentation [Text Block] | Overview and Basis of Presentation Overview Harvard Apparatus Regenerative Technology, Inc. (“HART” or the “Company”) is a biotechnology company developing bioengineered organs for life-threatening conditions. The Company’s technology initially is focused on restoring organ function to a patient’s esophagus or airways (the bronchus and the trachea). Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets. HART was incorporated in Delaware on May 3, 2012 by Harvard Bioscience, Inc. (“Harvard Bioscience”), as a wholly-owned subsidiary, to provide a means for separating Harvard Bioscience’s regenerative medicine business from its other businesses. On October 31, 2013, Harvard Bioscience contributed its regenerative medicine business assets, plus $ 15 Basis of Presentation Basic and diluted shares outstanding are the same for each period presented as all common stock equivalents would be antidilutive due to the net losses incurred. The financial statements reflect the Company’s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“GAAP”). Unaudited Interim Financial Information The accompanying interim balance sheet as of September 30, 2015 and consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2015 and 2014 are unaudited. The accompanying interim consolidated statements of cash flows for the nine months ended September 30, 2015 and 2014 are unaudited. The interim unaudited consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of September 30, 2015, its results of operations for the three and nine months ended September 30, 2015 and 2014, and the Company’s consolidated statements of cash flows for the nine months ended September 30, 2015 and 2014. The financial data and other information disclosed in these notes related to the nine month periods ended September 30, 2015 and 2014 are unaudited. The results for the three and nine months ended September 30, 2015 and 2014 are not necessarily indicative of results to be expected for the year ending December 31, 2015, any other interim periods or any future year or period. |
Summary of Significant Accounti
Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements | 9 Months Ended |
Sep. 30, 2015 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | 2. Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the financial statements for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K. There are no other recently issued accounting standards that are not yet effective that the Company believes would materially impact the financial statements. |
Capital Stock, Financing and Li
Capital Stock, Financing and Liquidity | 9 Months Ended |
Sep. 30, 2015 | |
Stockholders Equity Note [Abstract] | |
Stockholders Equity Note Disclosure [Text Block] | 3. Capital Stock, Financing and Liquidity On February 18, 2015, the Company closed an underwritten public offering of 2,070,000 1.75 695,857 0.01 8.75 9.7 1.1 8.6 During the three and nine months ended September 30, 2015, 330,714 535,993 1,653,570 2,679,965 159,864 799,320 The Company has incurred net losses of $ 41.7 since inception through September 30, 2015. The Company is currently investing significant resources in development and commercialization of products, including bioengineered organs, for use in the field of regenerative medicine |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2015 | |
Related Party Transactions [Abstract] | |
Related Party Transactions Disclosure [Text Block] | 4. Related Party Transactions During the three and nine months ended September 30, 2015, the Company recognized $ 0 165,000 Agreements with Harvard Bioscience From inception through April 17, 2015, Harvard Bioscience was considered to be a related party to the Company because David Green, the Company’s former Chairman and CEO, was also a director of Harvard Bioscience. After Mr. Green’s April 17, 2015 resignation as Chairman and CEO of HART, Harvard Bioscience is no longer considered a related party. Mr. Green is still a member of the Boards of Directors of both HART and Harvard Bioscience. In connection with the Separation of the Company from Harvard Bioscience, on October 31, 2013 the Company entered into a series of agreements with Harvard Bioscience, including a separation and distribution agreement, a transition services agreement, a tax sharing agreement, a sublicense agreement, a product distribution agreement, an intellectual property matters agreement and a sublease agreement. Some of these agreements require the Company to pay fees to Harvard Bioscience for services provided subsequent to the Separation. The transition services agreement expired on November 1, 2014. Expenses recorded under these agreements were $ 0.1 0.2 51,000 |
Concentrations
Concentrations | 9 Months Ended |
Sep. 30, 2015 | |
Concentrations Disclosure [Abstract] | |
Concentrations Disclosure [Text Block] | 5. Concentrations At the time of the Separation, the Company entered into a 10-year product distribution agreement with Harvard Bioscience under which each company will become the exclusive distributor for the other party forproducts such other party develops for sale in the markets served by the other. In addition, Harvard Bioscience has agreed that except for certain existing activities of its German subsidiary, to the extent that any Harvard Bioscience businesses desire to resell or distribute any bioreactor that is then manufactured by HART, HART will be the exclusive manufacturer of such bioreactors and Harvard Bioscience will purchase such bioreactors from the Company. Sales to Harvard Bioscience accounted for 100 |
Stock-Based Compensation
Stock-Based Compensation | 9 Months Ended |
Sep. 30, 2015 | |
Share-based Compensation [Abstract] | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 6. Stock-Based Compensation HART maintains the 2013 Equity Incentive Plan (the “2013 Plan”) for the benefit of certain of its officers, directors and employees. The securities underlying all options and awards granted under the 2013 Plan consist of shares of HART common stock. Additionally, equity awards related to shares of the Company’s common stock were issued from the 2013 Plan at the time of the Distribution to the holders of Harvard Bioscience equity awards as part of an adjustment (the “Adjustment”) to those equity awards to prevent a loss of value to the holders due to the Distribution. Harvard Bioscience award holders were also issued stock-based compensation awards in HART stock options and restricted stock units. HART recognizes compensation expense on those awards to former Harvard Bioscience employees who now are employed by HART, and does not recognize expense on the Adjustment awards given to individuals not now employed by HART. Additionally, HART records expense on grants made under the 2013 Plan to HART officers, directors and employees granted subsequent to the Adjustment. Harvard Bioscience maintains the Third Amended and Restated 2000 Stock Option and Incentive Plan, (as amended, the “Harvard Bioscience Plan”) for the benefit of certain of its officers, directors and employees. The securities underlying all options and awards granted under the Harvard Bioscience Plan consist of shares of Harvard Bioscience common stock. HART continues to record the expense on stock-based awards of Harvard Bioscience stock options and restricted stock units, issued by Harvard Bioscience, to former Harvard Bioscience employees now employed by HART. Harvard Apparatus Regenerative Technology, Inc. 2013 Equity Incentive Plan The 2013 Plan was adopted by the Board of Directors on October 11, 2013. The aggregate number of shares authorized for issuance under the Plan is 3,640,000 3,640,000 Stock Options Restricted Stock Units Stock Options Outstanding Weighted Average Exercise Price Restricted Stock Units Outstanding Grant Date Fair Value Balance at December 31, 2014 2,006,980 $ 4.73 7,980 $ 6.00 Granted 1,797,900 2.11 - - Exercised - - - - Vested (RSUs) - - (6,721) 6.00 Cancelled/forfeited (488,840) 4.22 (154) 6.00 Balance at September 30, 2015 3,316,040 $ 3.38 1,105 $ 6.00 Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Volatility 76% 77% Risk-free interest rate 1.77% 1.73% Expected holding period 6.09 years 6.10 years Dividend Yield -% -% The weighted average fair values of the options granted under the 2013 Plan during the nine months ended September 30, 2015 was $ 1.29 Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (in thousands) (in thousands) Research and development $ 171 $ 83 $ 524 $ 396 Sales and marketing 29 8 80 73 General and administrative 116 162 2,684 893 Total stock-based compensation $ 316 $ 253 $ 3,288 $ 1,362 The Company did not capitalize any stock-based compensation related to the 2013 Plan. In April 2015, David Green resigned as Chief Executive Officer, President and Chairman of the Board of Directors of HART. Mr. Green remained a member of the Board of Directors. Under the terms of Mr. Green’s employment agreement, certain equity awards immediately vested upon his resignation. This acceleration of vesting resulted in a non-cash stock based compensation expense of approximately $ 1.0 1.0 1.1 387,000 290,252 48,375 725,627 4.29 7 Harvard Bioscience Plan Award Information Stock Options Restricted Stock Units Stock Options Outstanding Weighted Average Exercise Price Restricted Stock Units Outstanding Grant Date Fair Value Balance at December 31, 2014 2,122,648 $ 2.84 171,557 $ 4.41 Granted - - - - Exercised (918,646) 2.73 - - Vested (RSUs) - - (88,648) 4.52 Cancelled/forfeited (6,585) 3.64 - - Balance at September 30, 2015 1,197,417 $ 2.92 82,909 $ 4.30 Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (in thousands) (in thousands) Research and development $ 11 $ 17 $ 31 $ 48 Sales and marketing 3 4 9 11 General and administrative 98 181 284 505 Total stock-based compensation $ 112 $ 202 $ 324 $ 564 The Company did not capitalize any stock-based compensation related to the Harvard Bioscience Plan. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | 7. Commitments and Contingencies From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that the Company expects to be material in relation to its business, financial condition, and results of operations or cash flows. |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Harvard Bioscience Plan [Member] | |
Stock Based Compensation [Line Items] | |
Schedule of Share-based Compensation, Activity [Table Text Block] | The following is a summary of stock option and restricted stock unit activity for the nine months ended September 30, 2015: Stock Options Restricted Stock Units Stock Options Outstanding Weighted Average Exercise Price Restricted Stock Units Outstanding Grant Date Fair Value Balance at December 31, 2014 2,122,648 $ 2.84 171,557 $ 4.41 Granted - - - - Exercised (918,646) 2.73 - - Vested (RSUs) - - (88,648) 4.52 Cancelled/forfeited (6,585) 3.64 - - Balance at September 30, 2015 1,197,417 $ 2.92 82,909 $ 4.30 |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Stock-based compensation expense from the Harvard Bioscience Plan for the three and nine months ended September 30, 2015 and 2014, respectively, was allocated as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (in thousands) (in thousands) Research and development $ 11 $ 17 $ 31 $ 48 Sales and marketing 3 4 9 11 General and administrative 98 181 284 505 Total stock-based compensation $ 112 $ 202 $ 324 $ 564 |
Equity Incentive Plan 2013 [Member] | |
Stock Based Compensation [Line Items] | |
Schedule of Share-based Compensation, Activity [Table Text Block] | The following is a summary of stock option and restricted stock unit activity for the nine months ended September 30, 2015: Stock Options Restricted Stock Units Stock Options Outstanding Weighted Average Exercise Price Restricted Stock Units Outstanding Grant Date Fair Value Balance at December 31, 2014 2,006,980 $ 4.73 7,980 $ 6.00 Granted 1,797,900 2.11 - - Exercised - - - - Vested (RSUs) - - (6,721) 6.00 Cancelled/forfeited (488,840) 4.22 (154) 6.00 Balance at September 30, 2015 3,316,040 $ 3.38 1,105 $ 6.00 |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Stock-based compensation expense for the three and nine months ended September 30, 2015 and 2014, respectively, was allocated as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 (in thousands) (in thousands) Research and development $ 171 $ 83 $ 524 $ 396 Sales and marketing 29 8 80 73 General and administrative 116 162 2,684 893 Total stock-based compensation $ 316 $ 253 $ 3,288 $ 1,362 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The following assumptions were used to estimate the fair value of stock options granted during the three and nine months ended September 30, 2015: Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Volatility 76% 77% Risk-free interest rate 1.77% 1.73% Expected holding period 6.09 years 6.10 years Dividend Yield -% -% |
Overview and Basis of Present14
Overview and Basis of Presentation (Details Textual) $ in Millions | 1 Months Ended |
Oct. 31, 2013USD ($) | |
Overview And Basis Of Presentation [Line Items] | |
Proceeds from Contributions from Parent | $ 15 |
Capital Stock, Financing and 15
Capital Stock, Financing and Liquidity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 23 Months Ended | ||||
Nov. 13, 2015 | Feb. 18, 2015 | Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Dec. 31, 2014 | |
Class of Stock [Line Items] | ||||||||
Common Stock, Shares, Issued | 12,652,075 | 12,652,075 | 12,652,075 | 7,856,607 | ||||
Payments of Stock Issuance Costs | $ 1,100 | |||||||
Proceeds from Issuance or Sale of Equity | 9,700 | |||||||
Net loss | $ 2,292 | $ 2,680 | $ 9,414 | $ 8,219 | ||||
Proceeds From Issuance Of Stock To Underwriters | $ 8,600 | |||||||
Common Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Common Stock, Shares, Issued | 2,070,000 | |||||||
Shares Issued, Price Per Share | $ 1.75 | |||||||
Net loss | $ 41,700 | |||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 1,653,570 | 2,679,965 | ||||||
Common Stock [Member] | Subsequent Event [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 799,320 | |||||||
Series B Convertible Preferred Stock [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Convertible Preferred Stock, Shares Reserved for Future Issuance | 695,857 | |||||||
Shares Issued, Price Per Share | $ 8.75 | |||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.01 | |||||||
Conversion of Stock, Shares Converted | 330,714 | 535,993 | ||||||
Series B Convertible Preferred Stock [Member] | Subsequent Event [Member] | ||||||||
Class of Stock [Line Items] | ||||||||
Conversion of Stock, Shares Converted | 159,864 |
Related Party Transactions (Det
Related Party Transactions (Details Textual) - USD ($) | 3 Months Ended | 4 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Apr. 17, 2015 | Sep. 30, 2015 | Sep. 30, 2014 | |
Director [Member] | |||||
Related Party Transaction [Line Items] | |||||
Related Party Transaction, Expenses from Transactions with Related Party | $ 0 | $ 165,000 | |||
Transition Services Agreement [Member] | |||||
Related Party Transaction [Line Items] | |||||
Operating Leases, Rent Expense | $ 100,000 | $ 51,000 | $ 200,000 |
Concentrations (Details Textual
Concentrations (Details Textual) | 9 Months Ended |
Sep. 30, 2015 | |
Concentrations Disclosure [Line Items] | |
Product Distribution Agreement Term | 10 years |
Accounts Receivable [Member] | Harvard Bioscience Plan [Member] | |
Concentrations Disclosure [Line Items] | |
Concentration Risk, Percentage | 100.00% |
Stock-Based Compensation (Detai
Stock-Based Compensation (Details) | 9 Months Ended |
Sep. 30, 2015$ / sharesshares | |
Harvard Bioscience Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Stock Options Outstanding, Balance | shares | 2,122,648 |
Stock Options Outstanding, Granted | shares | 0 |
Stock Options Outstanding, Exercised | shares | (918,646) |
Stock Options Outstanding, Vested (RSUs) | shares | 0 |
Stock Options Outstanding, Cancelled / forfeited | shares | (6,585) |
Stock Options Outstanding, Balance | shares | 1,197,417 |
Weighted Average Exercise Price, Balance | $ 2.84 |
Weighted Average Exercise Price, Granted | 0 |
Weighted Average Exercise Price, Exercised | 2.73 |
Weighted Average Exercise Price, Vested (RSUs) | 0 |
Weighted Average Exercise Price, Cancelled / forfeited | 3.64 |
Weighted Average Exercise Price, Balance | $ 2.92 |
Equity Incentive Plan 2013 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Stock Options Outstanding, Balance | shares | 2,006,980 |
Stock Options Outstanding, Granted | shares | 1,797,900 |
Stock Options Outstanding, Exercised | shares | 0 |
Stock Options Outstanding, Vested (RSUs) | shares | 0 |
Stock Options Outstanding, Cancelled / forfeited | shares | (488,840) |
Stock Options Outstanding, Balance | shares | 3,316,040 |
Weighted Average Exercise Price, Balance | $ 4.73 |
Weighted Average Exercise Price, Granted | 2.11 |
Weighted Average Exercise Price, Exercised | 0 |
Weighted Average Exercise Price, Vested (RSUs) | 0 |
Weighted Average Exercise Price, Cancelled / forfeited | 4.22 |
Weighted Average Exercise Price, Balance | $ 3.38 |
Restricted Stock Units (RSUs) [Member] | Harvard Bioscience Plan [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Restricted Stock Units Outstanding, Balance | shares | 171,557 |
Restricted Stock Units Outstanding, Granted | shares | 0 |
Restricted Stock Units Outstanding, Exercised | shares | 0 |
Restricted Stock Units Outstanding, Vested (RSUs) | shares | (88,648) |
Restricted Stock Units Outstanding, Cancelled / forfeited | shares | 0 |
Restricted Stock Units Outstanding, Balance | shares | 82,909 |
Grant Date Fair Value, Balance | $ 4.41 |
Grant Date Fair Value, Granted | 0 |
Grant Date Fair Value, Exercised | 0 |
Grant Date Fair Value, Vested (RSUs) | 4.52 |
Grant Date Fair Value, Cancelled / forfeited | 0 |
Grant Date Fair Value, Balance | $ 4.30 |
Restricted Stock Units (RSUs) [Member] | Equity Incentive Plan 2013 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Restricted Stock Units Outstanding, Balance | shares | 7,980 |
Restricted Stock Units Outstanding, Granted | shares | 0 |
Restricted Stock Units Outstanding, Exercised | shares | 0 |
Restricted Stock Units Outstanding, Vested (RSUs) | shares | (6,721) |
Restricted Stock Units Outstanding, Cancelled / forfeited | shares | (154) |
Restricted Stock Units Outstanding, Balance | shares | 1,105 |
Grant Date Fair Value, Balance | $ 6 |
Grant Date Fair Value, Granted | 0 |
Grant Date Fair Value, Exercised | 0 |
Grant Date Fair Value, Vested (RSUs) | 6 |
Grant Date Fair Value, Cancelled / forfeited | 6 |
Grant Date Fair Value, Balance | $ 6 |
Stock-Based Compensation (Det19
Stock-Based Compensation (Details 1) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | |
Harvard Bioscience Plan [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation | $ 112 | $ 202 | $ 324 | $ 564 |
Equity Incentive Plan 2013 [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation | 316 | 253 | 3,288 | 1,362 |
Selling and Marketing [Member] | Harvard Bioscience Plan [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation | 3 | 4 | 9 | 11 |
Selling and Marketing [Member] | Equity Incentive Plan 2013 [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation | 29 | 8 | 80 | 73 |
General and Administrative [Member] | Harvard Bioscience Plan [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation | 98 | 181 | 284 | 505 |
General and Administrative [Member] | Equity Incentive Plan 2013 [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation | 116 | 162 | 2,684 | 893 |
Research and Development [Member] | Harvard Bioscience Plan [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation | 11 | 17 | 31 | 48 |
Research and Development [Member] | Equity Incentive Plan 2013 [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Total stock-based compensation | $ 171 | $ 83 | $ 524 | $ 396 |
Stock-Based Compensation (Det20
Stock-Based Compensation (Details 2) - Equity Incentive Plan 2013 [Member] | 3 Months Ended | 9 Months Ended |
Sep. 30, 2015 | Sep. 30, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility | 76.00% | 77.00% |
Risk-free interest rate | 1.77% | 1.73% |
Expected holding period | 6 years 1 month 2 days | 6 years 1 month 6 days |
Dividend yield | 0.00% | 0.00% |
Stock-Based Compensation (Det21
Stock-Based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 9 Months Ended | ||
Apr. 30, 2015 | Sep. 30, 2015 | Sep. 30, 2014 | Dec. 31, 2014 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation, Total | $ 3,612 | $ 1,926 | ||
Equity Incentive Plan 2013 [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 1.29 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 3,640,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,797,900 | |||
Common Stock, Capital Shares Reserved for Future Issuance | 3,640,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 3.38 | $ 4.73 | ||
Equity Incentive Plan 2013 [Member] | President and Chief Executive Officer [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 725,627 | |||
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost | $ 1,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 387,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number | 290,252 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 48,375 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ 4.29 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 7 years | |||
Due to Employees, Current | $ 1,000 | |||
Share-based Compensation, Total | $ 1,100 |